Talaris Therapeutics Announces Upcoming Presentations on FCR001 at the Virtual 2021 American Transplant Congress
June 03 2021 - 7:00AM
Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage
cell therapy company developing therapies with the potential to
transform the standard of care in solid organ transplantation,
certain severe autoimmune diseases, and certain severe
non-malignant blood, immune and metabolic disorders, announced
upcoming presentations of data from the company’s Phase 2 study of
FCR001 at the American Transplant Congress taking place virtually
June 4-9, 2021.
The accepted oral presentation includes data on
the company’s analysis of peripheral blood chimerism as a biomarker
for transplantation tolerance. Phase 2 data indicate that one,
three, six, and 12-month chimerism levels are highly correlated
with each other and increasingly predictive over time of the
ability to withdraw immunosuppression at one year, suggesting that
whole blood and T-cell chimerism could be a valuable surrogate
marker of the ability to discontinue immunosuppression at one year
without rejection of the transplanted organ.
In addition, a poster will report on the
long-term follow-up of the company’s Phase 2 trial in living donor
kidney transplant recipients. Among the 37 subjects administered
FCR001, 26 displayed durable chimerism allowing for full withdrawal
of immunosuppression, and updated data show that all stable
chimeric subjects remain rejection-free with a minimum follow-up of
four years and the longest follow-up of almost 12 years.
The company will also be delivering two invited
presentations and two sponsored virtual lounge sessions.
INVITED ORAL PRESENTATIONS
Title: “Cellular Therapy to
Modify the Recipient Immune System”Presenter:
Suzanne Ildstad, Talaris TherapeuticsSession
Title: New Approaches to Tackling AlloimmunityDate
& Time: Friday, June 4, 3:00 p.m. ET
Title: “Peripheral Blood
Hematopoietic Chimerism: A Robust Biomarker for Transplantation
Tolerance”Session Title: What’s Hot and What’s
NewDate & Time: Wednesday, June 9, 12:25 p.m.
ET
ORAL ABSTRACT PRESENTATION
Title: “Peripheral Blood
Hematopoietic Chimerism: A Robust Biomarker for Transplantation
Tolerance”Presenter: David Tollerud, Talaris
TherapeuticsSession Title: Biomarkers, Immune
Assessment and Clinical Outcomes -
IAbstract: 18Date &
Time: Saturday, June 5, 5:05 p.m. ET
POSTER PRESENTATION
Title: “Long-Term
Follow-Up of a Phase 2 Clinical Trial to Induce Tolerance in Living
Donor Renal Transplant Recipients”Presenter: Joe
Leventhal, M.D., Ph.D., Northwestern Memorial
Hospital Session Title:
Tolerance: Clinical StudiesAbstract: 685
SPONSOR CONNECT SESSIONS
Session 1: Sunday, June 6,
11:30 a.m. - 12:00 p.m. ETPresenter: Suzanne Ildstad, Talaris
Therapeutics Title: FCR001 Investigational Cellular Therapy in
Living Donor Kidney Transplantation
Session 2: Monday, June 7,
11:30 a.m. - 12:00 p.m. ETPresenter: Nancy Krieger, Talaris
Therapeutics Title: FCR001 Investigational Cellular Therapy in
Living Donor Kidney Transplantation
About Talaris
TherapeuticsTalaris Therapeutics, Inc. is a late-clinical
stage biopharmaceutical company developing investigational,
one-time, allogeneic cell therapies with the potential to transform
the standard of care in solid organ transplantation, certain severe
autoimmune diseases, and certain severe non-malignant blood, immune
and metabolic disorders. Talaris maintains corporate offices in
Boston, Mass., and its cell processing facility in Louisville,
Ky.
Media ContactLisa
RaffenspergerTen Bridge
Communicationslisa@tenbridgecommunications.com(617)
903-8783
Investor ContactChris
BrinzeyWestwicke, an ICR
Companychris.brinzey@westwicke.com(339)
970-2843
Talaris Therapeutics (NASDAQ:TALS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Talaris Therapeutics (NASDAQ:TALS)
Historical Stock Chart
From Apr 2023 to Apr 2024